Skip to content
stoqly

Indivior

INDV Nasdaq Pharmaceuticals Financials FY2021–FY2025

Indivior's revenue rose 4.3% to $1.2 billion in fiscal 2025. Its operating margin was 21.1%, up from 3.2% a year earlier. Free cash flow was −$93 million, against $7 million a year earlier. It paid out $11 million in dividends and buybacks. The diluted share count fell 3.8%.

Last close · Oct 23, 2026

$34.47

2.4%
Value it Compare
Revenue Total sales reported in the income statement.
$1.2B
4.3% vs prior year
Operating margin Operating income as a share of revenue.
21.2%
18.0 pts
Net income Profit after all expenses, interest and tax.
$210M
2,900.0%
Free cash flow Cash from operations minus capital spending.
−$93.0M
1,428.6%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
$4.3B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
12.4x
On $2.79 EPS (TTM)

What Indivior does

No business description yet.

Legal name
Indivior Pharmaceuticals, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001628280-26-012237
0001625297

Revenue and margins

Indivior had $1.2B of revenue in fiscal 2025, up 4.3% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2021 to 2025, diluted EPS grew 5.0% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$93.0M in fiscal 2025, −7.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Indivior returned $11.0M to shareholders in fiscal 2025. The diluted share count fell 3.8%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Indivior yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$124M and divides by 128.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 12.4x · peers 17.1x · sector 28.4x.

Balance sheet

Cash, debt and the ratios that show how comfortably Indivior can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $1.1B$774M$410M$320M$195M
Debt incl. finance leases $242M$240M$243M$333M$319M
Net debt / EBITDA −3.8x——0.2x0.5x
Debt / equity 2.0x————
Interest coverage 7.9x−3.0x−4.3x0.9x5.8x
Current ratio 1.8x1.2x1.0x0.9x0.7x
Quick ratio 1.7x1.1x0.9x0.7x0.6x
Total assets $1.8B$1.8B$1.8B$1.3B$1.2B
Total liabilities $1.6B$1.7B$1.9B$1.7B$1.3B
Shareholders' equity $121M−$15.0M−$184M−$337M−$98.0M
Net debt (− = net cash) −$860M−$534M−$167M$13.0M$124M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.2M

5 insiders

Sold, 12 months

$2.8M

2 insiders

Of sales under plans

100%

$2.8M

DateInsiderTradeSharesPriceValueFiling
Aug 27, 2026 Woodrow D AndersonChief Accounting Officer Bought 1,500 $35.69 $0.1M Form 4
Aug 5, 2026 Woodrow D AndersonChief Accounting Officer Bought 1,500 $36.28 $0.1M Form 4
Jul 10, 2026 Christian HeidbrederChief Scientific Officer Sold plan 18,586 $41.14 $0.8M Form 4
Jun 11, 2026 Christian HeidbrederChief Scientific Officer Sold plan 18,586 $38.06 $0.7M Form 4
Jun 8, 2026 Ryan PreblickChief Financial Officer Sold plan 36,000 $37.70 $1.4M Form 4
Mar 13, 2026 Barbara RyanDirector Bought 8 $31.09 $0.0M Form 4
Mar 9, 2026 Barbara RyanDirector Bought 31 $32.56 $0.0M Form 4
Mar 6, 2026 Stuart A KingsleyDirector Bought 940 $31.87 $0.0M Form 4
Jan 5, 2026 Daniel A NinivaggiDirector Bought plan 775 $35.39 $0.0M Form 4
Jan 5, 2026 David E. WheadonDirector Bought plan 1,771 $35.39 $0.1M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✕ ✓ ✓
Cash from operations is positive ✕ ✓ ✕
Return on assets rose ✕ ✓ ✓
Cash from operations exceeds net income ✕ ✓ ✕
Debt fell relative to assets ✕ ✕ ✕
Current ratio rose ✕ ✕ ✕
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✓ ✕ ✕
Revenue rose relative to assets ✓ ✓ ✓
F-score 3 / 96 / 94 / 9
Accruals ratio 9.9%−1.9%18.8%
Altman Z'' −1.20−1.60−0.70

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Indivior INDV $4.3B 4.3% 21.2% −7.5% — 12.4x 4
Acadia Pharmaceuticals ACAD $3.4B 11.9% 9.8% 9.8% — 8.9x — Compare →
Alkermes ALKS $7.6B −5.3% 17.2% 32.6% — 114.8x — Compare →
ANI Pharmaceuticals ANIP $1.6B 43.8% 12.6% 19.4% 15.9% 15.7x 6 Compare →
Collegium Pharmaceutical COLL $746M 23.6% 23.0% 42.0% 53.4% 18.5x 6 Compare →

5 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue $791M $901M $1.1B $1.2B $1.2B
Gross profit $664M $749M $919M $957M $994M
Research and development $52.0M $72.0M $106M $107M $97.0M
Operating income $213M −$81.0M −$152M $38.0M $262M
Interest expense $27.0M $27.0M $35.0M $41.0M $45.0M
Pretax income $190M −$89.0M −$145M $20.0M $239M
Income tax −$15.0M −$44.0M −$19.0M $13.0M $29.0M
Net income $205M −$44.0M −$126M $7.0M $210M
Diluted EPS $1.35 −$0.32 −$0.92 $0.05 $1.64
Diluted shares 0.15B 0.14B 0.14B 0.13B 0.13B
Cash flow
Cash from operations $353M −$4.0M −$300M $36.0M −$27.0M
Capital expenditure $4.0M $5.0M $8.0M $29.0M $66.0M
Free cash flow $349M −$9.0M −$308M $7.0M −$93.0M
Depreciation and amortization $15.0M $16.0M $15.0M $16.0M $10.0M
Stock-based compensation $11.0M $16.0M $21.0M $24.0M $26.0M
Acquisitions $0.0M $0.0M $129M $0.0M $0.0M
Share buybacks $101M $90.0M $33.0M $173M $11.0M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $101M $90.0M $33.0M $173M $11.0M
Balance sheet
Cash and short-term investments $1.1B $774M $410M $320M $195M
Total debt $242M $240M $243M $333M $319M
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $1.4B $1.3B $1.3B $827M $652M
Current liabilities $804M $1.0B $1.3B $924M $914M
Inventory $95.0M $114M $126M $167M $153M
Property and equipment, net $58.0M $54.0M $84.0M $100M $144M
Total assets $1.8B $1.8B $1.8B $1.3B $1.2B
Total liabilities $1.6B $1.7B $1.9B $1.7B $1.3B
Shareholders' equity $121M −$15.0M −$184M −$337M −$98.0M
Margins
Gross margin 83.9% 83.1% 84.1% 80.6% 80.2%
Operating margin 26.9% −9.0% −13.9% 3.2% 21.2%
EBITDA margin 28.8% −7.2% −12.5% 4.6% 22.0%
Net margin 25.9% −4.9% −11.5% 0.6% 17.0%
FCF margin 44.1% −1.0% −28.2% 0.6% −7.5%
Returns
Return on capital employed — −9.1% −24.8% 8.8% 77.2%
Return on assets — −2.4% −7.1% 0.5% 16.7%
Growth
Revenue growth — 13.9% 21.3% 8.7% 4.3%
Net income growth — −121.5% — — 2,900.0%
EPS growth — −123.7% — — 3,180.0%
FCF growth — −102.6% — — −1,428.6%
Share count change — −8.5% −1.4% −2.9% −3.8%
Financial health
Net debt / EBITDA −3.8x — — 0.2x 0.5x
Debt / equity 2.0x — — — —
Interest coverage 7.9x −3.0x −4.3x 0.9x 5.8x
Current ratio 1.8x 1.2x 1.0x 0.9x 0.7x
Quick ratio 1.7x 1.1x 0.9x 0.7x 0.6x
Capital allocation
Capex / revenue 0.5% 0.6% 0.7% 2.4% 5.3%
Stock comp / revenue 1.4% 1.8% 1.9% 2.0% 2.1%
Payouts / FCF 28.9% — — 2,471.4% —
Quality scores
Piotroski F-score — — 3.0 6.0 4.0
Altman Z'' 5.8 3.0 −1.2 −1.6 −0.7
Accruals ratio — −2.2% 9.9% −1.9% 18.8%

Source: SEC EDGAR XBRL filings (CIK 0001625297). Data updated October 23, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open